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Objectives: To determine the incidence of adverse
drug events (ADEs) and assess their severity and
preventability in four Saudi hospitals.
Design: Prospective cohort study.
Setting: The study included patients admitted to
medical, surgical and intensive care units (ICUs) of
four hospitals in Saudi Arabia. These hospitals include
a 900-bed tertiary teaching hospital, a 400-bed private
hospital, a 1400-bed large government hospital and a
350-bed small government hospital.
Participants: All patients (≥12 years) admitted to the
study units over 4 months.
Primary and secondary outcome measures:
Incidents were collected by pharmacists and reviewed
by independent clinicians. Reviewers classified the
identified incidents as ADEs, potential ADEs (PADEs)
or medication errors and then determined their severity
and preventability.
Results: We followed 4041 patients from admission
to discharge. Of these, 3985 patients had complete
data for analysis. The mean±SD age of patients in the
analysed cohort was 43.4±19.0 years. A total of 1676
ADEs were identified by pharmacists during the
medical chart review. Clinician reviewers accepted 1531
(91.4%) of the incidents identified by the pharmacists
(245 ADEs, 677 PADEs and 609 medication errors with
low risk of causing harm). The incidence of ADEs was
6.1 (95% CI 5.4 to 6.9) per 100 admissions and 7.9
(95% CI 6.9 to 8.9) per 1000 patient-days. The
occurrence of ADEs was most common in ICUs (149
(60.8%)) followed by medical (67 (27.3%)) and
surgical (29 (11.8%)) units. In terms of severity, 129
(52.7%) of the ADEs were significant, 91 (37.1%) were
serious, 22 (9%) were life-threatening and three
(1.2%) were fatal.
Conclusions: We found that ADEs were common in
Saudi hospitals, especially in ICUs, causing significant
morbidity and mortality. Future studies should focus
on investigating the root causes of ADEs at the
prescribing stage, and development and testing of
interventions to minimise harm from medications.
INTRODUCTION
Adverse drug events (ADEs) are a major cause
of morbidity, mortality and increased health-
care costs and hospitalisation.1–3 An ADE is
deﬁned as an injury caused by a medication.4
They are largely preventable and occur
mostly at the prescribing stage of the medica-
tion use process.2 4 5 The incidence of ADEs
reported in the literature varies signiﬁcantly
between countries, largely because of the dif-
ferences in available drug products, prac-
tices, training, study methodology and
patient safety initiatives among countries.
Early in 1995, Bates et al2 reported an inci-
dence of 6.5 per 100 admissions in the USA;
however, using the same methods, a study in
Japan reported an incidence of 17 per 100
admissions,4 suggesting real differences
between these two countries. In Saudi
Arabia, a single hospital study reported an
incidence of 8.5 per 100 admissions,5 and a
cross-sectional study in Morocco reported an
incidence of 4.2 per 100 admissions.6 A
recent international study using hospital
datasets estimated the prevalence of ADEs to
be 3.2% in England, 4.8% in Germany and
5.6% in the USA.7 It is important to mention
that the incidence of preventable ADEs was
Strengths and limitations of this study
▪ This study is one of the largest investigating the
incidence of adverse drug events (ADEs) in the
Middle East.
▪ This study is limited by a lack of hospitals from
small towns and rural areas, and these settings
may have an even higher incidence of ADEs.
▪ Our study findings are not generalisable to
overall Saudi Arabia because the study was con-
ducted in Riyadh only.
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estimated by a population-based study to be 13.8 per
1000 person-years.8
Despite the evidence that ADEs are common and could
be life-threatening, little attempt has been made in
Saudi Arabia to detect and estimate the incidence of
ADEs in hospitalised patients. Such a paucity of research
hinders the development of prevention strategies to
improve patient safety. To date, one prospective chart
review study has been conducted in a single teaching
hospital in the Saudi setting.5 Therefore we sought to
estimate incident ADEs in a larger patient sample from
different hospitals with diverse settings and varying prac-
tices and strategies for managing patients. Therefore,
the objective of our study was to estimate the incidence
and risk factors associated with ADEs in Saudi hospitals
and determine their severity and preventability.
METHODS
Study design and setting
The ADEs in Saudi Arabia (ADESA) project was a
4-month prospective cohort study involving four hospi-
tals with diverse settings. These hospitals included a
900-bed tertiary teaching hospital, a 400-bed private hos-
pital, a 1400-bed large government hospital and a
350-bed small government hospital. We randomly
selected medical, surgical and intensive care units
(ICUs) from these hospitals and excluded obstetrics and
paediatric units because of the lower frequency of use of
medications within these units. We included patients
older than 12 years of age admitted for more than
24 hours during the 4-month study period. None of the
hospitals had electronic medical records or decision
support systems. Instead, hospitals used paper-based
systems where physician notes (including prescribed
medications) and nursing notes (including daily admi-
nistered medications) were handwritten and kept in
patient charts. Medication orders were sent to the
inpatient pharmacies and dispensed using unit dose
systems.
Definitions
Each incident was deﬁned as an ADE (preventable and
non-preventable), potential ADE (PADE) (which was
classiﬁed as either intercepted or non-intercepted), or a
medication error with low risk of causing harm. We
deﬁned ADE as any injury resulting from medical inter-
ventions related to a drug and includes both adverse
drug reaction (ADR) in which no error occurred and
complications resulting from medication errors.2 9 10
Non-preventable ADEs, also known as ADRs, are deﬁned
by the WHO as ‘a response to a drug which is noxious
and unintended, and which occurs at doses used in man
for prophylaxis, diagnosis, or therapy of disease, or for
the modiﬁcation of physiological function’.11 A non-
preventable ADE is an injury with no error in the medi-
cation process. An example of this would be an allergic
reaction in a patient not previously known to be allergic
to that particular medication. Preventable ADEs were
those that result from medication errors at any stage of
the medication use process.2 An example of this would
be an anaphylactic reaction to an antibiotic that the
patient is known to be allergic to. Preventability was
further classiﬁed into deﬁnitely preventable/non-
preventable and probably preventable/non-preventable.
A PADE was an error that carries a risk of causing injury
related to the use of a medication but harm did not
occur, either because of speciﬁc circumstances or
because the error was intercepted.9 Intercepted PADEs
were those that had the potential to cause injury but did
not reach the patient because they were intercepted by
someone during the medication use process.
Non-intercepted PADEs were those with the potential to
cause harm but failed to do so after the medication
reached the patient.9 Medication errors with a low risk
of causing harm included those with minimal risk to
cause ADEs or PADEs. Comorbidities were determined
using Charlson’s Comorbidity Index, which is a method
of classifying comorbidities of patients according to the
International Classiﬁcation of Disease (ICD). Each
comorbidity class has an associated weight of 1, 2, 3 or
6. The sum of all weights results in a single comorbidity
score for each patient, with higher scores predictive of
adverse outcomes such as mortality or high resource
use.
Data collection and classification of incidents
Data were collected as described in detail elsewhere.5
Brieﬂy, trained clinical pharmacists collected data each
day during the study period. In addition, all nurses
working in the particular units were invited to attend
monthly in-service presentations on the study to increase
their awareness about ADE reporting. The pharmacists
reviewed patients’ medical charts of all admitted patients
in each of the participating units to report demographic
characteristics of patients, comorbidity, and the number
of medications. When incidents were noted, the phar-
macists wrote a detailed description of each incident
and captured the relevant patient characteristics and
event history.
Two independent clinicians who were not involved in
the data collection process were provided with a study
manual that contained study terminology and a guide
on the assessment of the severity and preventability of
an incident. The manual included examples of incidents
and their severity classiﬁcations. The severity of the inci-
dents was categorised as signiﬁcant, serious, life-
threatening or fatal using a methodology developed by
the Brigham and Women’s Hospital’s Center for Patient
Safety Research and Practice.2 The study manual served
as a guide for the reviewers to independently review the
incidents and decide on inclusion of incidents and
further classify them as ADEs, PADEs or medication
errors with low risk of causing harm. They were then
able to assess severity and preventability. Preventability
categories were deﬁned as follows: deﬁnitely
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preventable, probably preventable, deﬁnitely not pre-
ventable or probably not preventable.2 In the event of
disagreement on the classiﬁcation of the incidents, the
clinicians called for a meeting to decide whether to
include or exclude the incidents. The primary outcomes
of this study were incidence of ADEs, PADEs and medi-
cation errors with low risk of causing harm, as deﬁned
previously. The secondary outcomes were the severity of
events, their preventability, and associated risk factors.
The research and ethics committees of the four hospi-
tals approved this study.
Data analysis
We calculated the overall incidence per 100 admissions
and crude rate per 1000 patient-days with 95% CIs. In
addition, the incidence was calculated by hospital and
by unit type. Continuous variables are presented as
mean±SD and categorical variables as number and per-
centage. Inter-rater reliability was assessed using the κ
statistic for assessment of the presence of an ADE and its
preventability and severity. To evaluate the univariate
association of potential risk factors with ADEs, we used
univariate logistic regression. The variables included in
the univariate analysis were age, gender, Charlson’s
Comorbidity Index weight, length of hospital stay,
number of medications, and service type. Variables
found to be statistically signiﬁcant (p<0.05) in the uni-
variate analysis were included in the multivariate logistic
regression ﬁnal model. Statistical analyses were con-
ducted using SPSS software V.22.0.
RESULTS
Demographic characteristics of the patients
Clinical pharmacists reviewed the medical charts of 4041
patients. Complete data for 3985 patients were analysed
(table 1). The total length of hospital stay for patients
was 30 996 days. The study was conducted in four hospi-
tals in Riyadh, Saudi Arabia (977 patients from a teach-
ing hospital, 2033 patients from a private hospital, 683
patients from a large government hospital, and 292
patients from a small government hospital). There was a
slight majority of male patients (52.7%) (table 1). The
patients were admitted to one of the three services
(medical, 1352; surgery, 1771; ICU, 862). The mean
length of hospital stay was 8.1±10.2 days and the mean
age of the patients was 43.4±19.0 years (table 1).
Incidents review and classification
The pharmacists’ chart reviews in the four hospitals
identiﬁed 1676 cases of ADEs, PADEs and medication
errors. Physicians reviewed and accepted 1531 (91.3%)
of the cases, which were classiﬁed as 609 (39.8%) medi-
cation errors with low risk of harm, 677 (44.2%) PADEs,
and 245 (16%) ADEs (ﬁgure 1). Among the ADEs, 85
(34.7%) were deemed preventable and 160 (65.3%)
were judged to be non-preventable (table 2). The major-
ity of the preventable ADEs occurred at the prescribing
stage (75; 88.2%) followed by the administering stage
(7; 8.2%), dispensing stage (2; 2.4%) and monitoring
stage (1; 1.2%). Over half (129 (52.7%)) of the ADEs
were signiﬁcant, 91 (37.1%) were serious, 22 (9%) were
life-threatening, and 3 (1.2%) were fatal. Of the 85 pre-
ventable ADEs, 36 (42.4%) were signiﬁcant, 38 (44.7%)
were serious, 10 (11.9%) were life-threatening and 1
(1.2%) was fatal. Among PADEs, 213 (31.9%) were inter-
cepted by the medical staff. Regarding severity of
PADEs, 383 (56.6%) were signiﬁcant, 271 (40%) were
serious and 23 (3.4%) were life-threatening.
Overall incidence of ADEs and medication errors with low
risk of causing harm
The incidence of ADEs per 100 admissions was 6.1 (95%
CI 5.4 to 6.9) and the incidence of PADEs was 16.9
(95% CI 15.7 to 18.3) per 100 admissions (table 2). The
incidence of medication errors with low risk of causing
harm was 15.3 (95% CI 14.1 to 16.5) per 100 admissions,
and the incidence of preventable ADEs was 2.1 (95% CI
1.7 to 2.6) per 100 admissions. The incidence of non-
preventable ADEs was 4.0 (95% CI 3.4 to 4.6) per 100
admissions, and the incidence of intercepted PADEs was
5.3 (95% CI 4.6 to 6.1) per 100 admissions (table 2).
Incidents of preventable ADEs, PADEs and medication
errors with low risk of causing harm most commonly
occurred at the prescribing stage (1288 (84.1%)), fol-
lowed by the dispensing stage (69 (4.5%)) and the
administering stage (43 (2.8%)). Table 3 shows the dis-
tribution of incidents among the four hospitals.
Examples of PADEs at different stages of the medication
use process are listed in online supplementary appendix
Table 1 Demographic characteristics of 3985 patients





Male 2102 (52.7) –













Medicine 1352 (33.9) –
Surgery 1771 (44.5) –
Intensive care unit 862 (21.6) –
Age, years – 43.4±19.0




Number of medications – 2.5±2.9
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A. The incidence of ADEs was highest in the large gov-
ernment hospital (16.6 (95% CI 13.5 to 20.2) per 1000
patient-days and 32.9 (95% CI 27.7 to 38.4) per 100
admissions) followed by the teaching hospital (8.7 (95%
CI 6.9 to 10.6) per 1000 patient-days and 8.5 (95% CI
6.8 to 10.4) per 100 admissions) (table 3).
Figure 1 Study flow chart.











Medication errors with low risk of causing harm 609 39.8 15.3 (14.1 to 16.5) 19.6 (18.7 to 21.2)
PADEs 677 44.2 16.9 (15.7 to 18.3) 21.8 (20.2 to 23.5)
Intercepted PADEs (n=213) 5.3 (4.6 to 6.1) 6.8 (5.9 to 7.8)
Not intercepted PADEs (n=464) 11.6 (10.6 to 12.7) 14.9 (13.6 to 16.3)
ADEs (harm) 245 16 6.1 (5.4 to 6.9) 7.9 (6.9 to 8.9)
Preventable ADEs (n=85) 2.1 (1.7 to 2.6) 2.7 (2.2 to 3.3)
Non-preventable ADEs (n=160) 4.0 (3.4 to 4.6) 5.1 (4.4 to 6.0)
Medication errors with low risk of causing harm include those with low risk of causing ADEs or PADEs.
4 Aljadhey H, et al. BMJ Open 2016;6:e010831. doi:10.1136/bmjopen-2015-010831
Open Access
The incidence of PADEs was predominantly higher in
the private hospital (367; 23.9%). Medication errors
were mostly seen in the private hospital (367; 23.9%).
Classification of ADE incidents by service type
The incidence of ADEs was highest in the ICUs at 13.7
(95% CI 11.6 to 16.1) per 1000 patients-days and 17.4 (95%
CI 14.7 to 20.3) per 100 admissions, followed by the medical
units at 6.1 (95% CI 4.7 to 7.7) per 1000 patients-days
and 4.8 (95% CI 3.8 to 6.1) per 100 admissions (table 4).
Medication classes involved in ADEs, PADEs and
medication errors with low risk of causing harm
Anticoagulants (21.6%) and antibiotics (20.8%) were
the most common medication classes associated with
ADEs. Medication classes most commonly associated
with PADEs were antibiotics (31.3%) followed by anticoa-
gulants (17.3%) and antihypertensives (9.3%) (table 5).
Agreement of physicians’ reviews on the classification of
the incidents
The κ value was 0.71 for the presence of ADEs, 0.67 for
the presence of medication errors, and 0.62 for the pres-
ence of PADEs. The κ value for preventability of ADEs was
0.68 (deﬁnitely or probably preventable vs deﬁnitely or
probably not preventable). For the severity of ADEs, the κ
value was 0.74 (fatal vs signiﬁcant, serious or life-
threatening), 0.63 (life-threatening vs signiﬁcant, serious or
fatal), 0.52 (signiﬁcant vs serious, life-threatening or fatal),
and 0.48 (serious vs life-threatening or fatal) (table 6).
Factors associated with ADEs
Factors signiﬁcantly associated with ADEs included age
(OR 1.012; 95% CI 1.003 to 1.021), number of medica-
tions (OR 1.062; 95% CI 1.008 to 1.119), length of hos-
pital stay (OR 1.025; 95% CI 1.015 to 1.035) and
admission to ICUs (OR 3.276; 95% CI 2.005 to 5.354)
and medical units (OR 1.736; 95% CI 1.078 to 2.796)
(table 7). Gender was not signiﬁcantly associated with
ADEs (p=0.248); therefore, it was not included in the
multivariate analysis.








ADE incidence per 100
admissions (95% CI)
Hospital 1 83 9585 8.7 (6.9 to 10.6) 977 8.5 (6.8 to 10.4)
Hospital 2 53 9032 5.9 (4.4 to 7.6) 2033 2.6 (2.1 to 3.3)
Hospital 3 13 6613 2.1 (1.1 to 3.2) 683 2.1 (1.1 to 3.2)
Hospital 4 96 5766 16.6 (13.5 to 20.2) 292 32.9 (27.7 to 38.4)
Hospital 1, teaching hospital; Hospital 2, private hospital; Hospital 3, small government hospital; Hospital 4, large government hospital.
Table 4 Classification of incidence of adverse drug events (ADEs) by type of service
Unit ADEs Patient-days, n
ADE crude rate per 1000
patient-days (95% CI) Admissions, n
ADE incidence per 100
admissions (95% CI)
Medical 66 10 767 6.1 (4.7 to 7.7) 1352 4.8 (3.8 to 6.1)
Surgical 29 9310 3.1 (2.1 to 4.4) 1771 1.6 (1.1 to 2.3)
ICU 150 10 919 13.7 (11.6 to 16.1) 862 17.4 (14.7 to 20.3)
ICU, intensive care unit.
Table 5 Medication classes involved in adverse drug
events (ADEs), potential ADEs (PADEs) and medication













Antibiotics 51 (20.8) 212 (31.3) 193 (31.7)
Anticoagulants 53 (21.6) 117 (17.3) 92 (15.1)
Antihypertensives 49 (20) 63 (9.3) 61 (10)
NSAIDs 11 (4.5) 41 (6.1) 55 (9)
GI medicines 4 (1.6) 43 (6.4) 39 (6.4)
Antidiabetics 5 (2) 32 (4.7) 26 (4.3)
Steroids 14 (5.7) 12 (1.8) 17 (2.8)
Electrolytes 7 (2.9) 19 (2.8) 6 (1)
Cardiovascular
medicines
4 (1.6) 15 (2.2) 11 (1.8)
Dyslipidaemic
agents
7 (2.9) 16 (2.4) 6 (1)
Analgesics 4 (1.6) 9 (1.3) 15 (2.5)
Antiasthmatics 5 (2) 14 (2.1) 6 (1)
Antituberculosis 3 (1.2) 11 (1.6) 7 (1.1)
Vitamins 0 8 (1.2) 5 (0.8)
Antifungals 1 (0.5) 4 (0.6) 6 (1)
Antiseizures 5 (2) 3 (0.4) 2 (0.3)
Antipsychotics 1 (0.5) 3 (0.4) 6 (1)
Thyroid agents 0 5 (0.7) 3 (0.5)
Antivirals 4 (1.6) 2 (0.3) 1 (0.2)
Antihistamines 1 (0.5) 3 (0.4) 1 (0.2)
Sedatives 4 (1.6) 1 (0.1) 0
Anticancers 0 3 (0.4) 2 (0.3)
Others 12 (4.9) 41 (6.1) 49 (8)
GI, gastrointestinal; NSAID, non-steroidal anti-inflammatory drug.
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DISCUSSION
In this study we evaluated the incidence of ADEs and
found that they were common, with one-third caused by
medication errors judged to be preventable. Errors
resulting from preventable ADEs were most common at
the prescribing stage followed by the dispensing and
administering stages. Most of the preventable ADEs were
judged to be serious. The incidence of ADEs reported
in our study is similar to that found in previous
studies.2 5 However, a higher incidence was reported in
Japan.4 The differences between our study results and
the results from the Japanese study could be due to the
longer hospital stay in Japan and differences in health-
care systems between the countries. The similarity
between our ﬁndings and the US study may be due to
the use of the same methods for data collection, ADE
detection, and event classiﬁcation and the similarities in
the healthcare systems. The incidence at the prescribing
stage in our study was higher than reported in Malaysia
(25.15%),12 Indonesia (20.4%)13 and Thailand (1%).14
The κ values reported in our study range from sub-
stantial to moderate according to the measure of the
strength of agreement suggested by Landis and Koch.15
The lowest level of agreement in the present study was
reported for judgement regarding the severity of the
incidents (0.48 and 0.52). However, a similar study
reported κ values lower than those found in our study
(0.32 and 0.37).2
We included 3985 patients and found 245 ADEs, of
which 35% were judged to be preventable. Gurwitz et al8
identiﬁed 546 ADEs during 2403 nursing home resi-
dence admissions and reported that 51% of the
observed ADEs were preventable. Bates et al2 determined
the incidence of ADEs in 4031 patients and found 247
ADEs, of which 28% were deemed preventable. In 2009,
Hug et al16 assessed the occurrence of ADEs in 1200
patients from six community hospitals and identiﬁed
180 ADEs, of which 75% were preventable. A multicen-
tre cohort study of 3459 patients identiﬁed 1010 ADEs
and found that 14% of the identiﬁed ADEs were
preventable.4
Regarding PADEs, we noticed that only one-third of
the events were intercepted. It is noteworthy to highlight
that three of the four hospitals had clinical pharmacists
monitoring patient treatments and most of the inter-
cepted PADEs were in those hospitals.
Our study revealed that ADEs were associated with
admission to ICUs and older age. Consistent with our
results, other studies also reported that admission to
ICUs4 17 and older age4 8 were major factors associated
with ADEs. In support of this ﬁnding, perhaps special
care should be given to older people who are admitted
to ICUs because of the added risk of combining two risk
factors.
Several important basic medication safety practices are
not widely adopted in most Saudi hospitals.18 19
Table 6 Inter-rater reliability of the incident type and their severity and preventability
Severity Agreement, % κ value
Exclude vs ADEs, PADE or medication error 56.4 0.63
ADEs vs PADE, medication error or exclude 93.6 0.71
PADEs vs ADE, medication error or exclude 70.9 0.62
Medication error vs ADEs, PADE or exclude 93.7 0.67
Preventable vs non-preventable ADEs 92.2 0.68
Fatal vs life-threatening, serious or significant 100 0.74
Life-threatening vs fatal, serious or significant 100 0.63
Serious vs fatal, life-threatening or significant 60.5 0.48
Significant vs fatal, life-threatening or serious 84.2 0.52
ADE, adverse drug event; PADE, potential ADE.
Table 7 Factors associated with adverse drug events
95% CI
p Value Adjusted OR
95% CI
p ValueFactor Unadjusted OR Lower Upper Lower Upper
Age 1.024 1.017 1.032 <0.001 1.012 1.003 1.021 0.009
Number of medications 1.193 1.148 1.240 <0.001 1.062 1.008 1.119 0.023
Charlson’s Comorbidity Index weight 1.251 1.158 1.352 <0.001 1.041 0.937 1.157 0.452
Length of hospital stay 1.042 1.034 1.051 <0.001 1.025 1.015 1.035 <0.001
Gender (male)* 0.848 0.642 1.121 0.248 – – – –
ICU† 7.786 5.259 11.528 <0.001 3.276 2.005 5.354 <0.001
Medical unit† 2.539 1.664 3.872 <0.001 1.736 1.078 2.796 0.023
*Reference category: female.
†Reference category: surgery.
ICU, intensive care unit.
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Therefore, there are opportunities for improving the
safe use of medications and preventing ADEs in hospi-
tals in Saudi Arabia. On a national level, the Saudi Food
Drug Authority may lead efforts to prevent ADRs, and
the Saudi Medication Safety Centre may lead initiatives
to prevent medication errors. For example, the use of
pharmacists to ascertain complete medication histories
at admission and provide discharge counselling reduced
the incidence of ADEs.20 21 Although reporting is a
good tool to identify and prevent ADEs, under-reporting
is a common challenge in Saudi hospitals.22
There is lack of literature about incident medication
errors in South-East Asian23 and Middle Eastern coun-
tries.24 Future research could focus on investigating the
causes of ADEs that occur during the medication use
process, especially at the prescribing stage. More research
is needed on the causes of ADEs using both qualitative
and quantitative methodologies with the use of standard
deﬁnitions of events and severity classiﬁcation. Using
methods similar to those used in this study, the beneﬁts
of interventions to prevent ADEs can be estimated and
compared with a rigorously determined baseline.
This study is limited by a lack of hospitals from small
towns and rural areas and it is thought that these set-
tings have an even higher incidence of ADEs. Finally,
our study ﬁndings are not generalisable to Saudi Arabia
overall because the study was conducted in Riyadh only.
In conclusion, ADEs are common in Saudi hospitals,
especially in the ICUs, causing signiﬁcant morbidity
and mortality. While there are variations in the inci-
dence of ADEs among countries, there are prospects for
preventing them. Interventions that are effective in
other countries should be tested in Saudi Arabia. Such
interventions may include, but are not limited to, imple-
mentation of computerised physician entry with a clin-
ical decision support system,16 involvement of clinical
pharmacists as part of the medical team during physi-
cians’ rounds,25–27 medication reconciliation to obtain
accurate medication histories at hospital admission, unit
transfers during hospitalisation and discharge from hos-
pital,28 and changing the currently available paper-based
system to an electronic medical records system.29
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